

Aralast™ NP, Glassia®, Prolastin-C®, and Zemaira® (alpha1-proteinase inhibitor [human])

When requesting Aralast® NP, Glassia®, Prolastin-C®, and Zemaira® (alpha₁-proteinase inhibitor [human]), the individual requiring treatment must be diagnosed with an FDA-approved indication or approved compendial use and meet the specific coverage guidelines and applicable safety criteria for the covered indication.

FDA-approved indication

Aralast NP, Glassia, Prolastin-C and Zemaira are an alpha₁-proteinase inhibitor indicated for chronic augmentation and maintenance therapy in adults with clinically evident emphysema due to severe congenital deficiency of alpha₁-antitrypsin deficiency.

Approved Off-label Compendial Use

Panniculitis due to alpha1-antitrypsin (AAT) deficiency

Coverage Guidelines

The individual must have a diagnosis of emphysema due to alpha₁-antitrypsin (AAT) deficiency OR panniculitis due to AAT deficiency.

For emphysema due to AAT deficiency:

The individual must meet BOTH of the following criteria for approval:

- Baseline (pretreatment) AAT serum concentration is less than 11 micromol/L (less than 80 mg/dL)
- Currently a nonsmoker

Approval duration: 12 months

Dosing Recommendation

The recommended dose is 60 mg/kg body weight administered once weekly by intravenous infusion.

References

1. Aralast NP® [prescribing information]. Lexington, MA: Shire; December 2018.
2. Zemaira® [prescribing information]. Kankakee, IL: CSL Behring; April 2019.
3. Prolastin®-C [prescribing information]. Research Triangle Park, NC: Grifols Therapeutics; June 2018.
4. Prolastin®-C Liquid [prescribing information]. Research Triangle Park, NC: Grifols Therapeutics; August 2018.
5. Glassia® [prescribing information]. Lexington, MA: Shire; June 2017.
6. Brantly ML, Lascano JE, Shahmohammadi A. Intravenous alpha-1 antitrypsin therapy for alpha-1 antitrypsin deficiency: the current state of the evidence. *Chronc Obstr Pulm Dis*. 2018;6(1):100-114.
7. American Thoracic Society and the European Respiratory Society. Standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. *Am J Respir Crit Care Med*. 2003;168:818-900. Available at: <http://www.atsjournals.org/doi/abs/10.1164/rccm.168.7.818>. Accessed on September 12, 2019.
8. Miravittles M, Dirksen A, Ferrarotti I, et al. European Respiratory Society statement: diagnosis and treatment of pulmonary disease in alpha1-antitrypsin deficiency. *Eur Respir J*. 2017;50(5). Available at: <https://erj.ersjournals.com/content/erj/50/5/1700610.full.pdf>. Accessed on October 3, 2019.
9. Marciniuk DD, Hernandez P, Balter M, et al. Alpha-1 antitrypsin deficiency targeted testing and augmentation therapy: A Canadian Thoracic Society clinical practice guideline. *Can Respir J*. 2012;19:109-116. Available at <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3373286/pdf/crj19109.pdf>. Accessed on October 8, 2018.
10. Sandhaus RA, Turino G, Brantly ML, et al. The diagnosis and management of alpha-1 antitrypsin deficiency in the adult. *Chronic Obstr Pulm Dis*. 2016;3(3):668-682. Available at <http://journal.copdfoundation.org/Portals/0/JCOPDF/Files/Volume3-Issue3/JCOPDF-2015-0182-Sandhaus.pdf>. Accessed on October 8, 2018.
11. Chowdhury MMU, Williams EJ, Morris JS, et al. Severe panniculitis caused by homozygous ZZ α_1 -antitrypsin deficiency treated successfully with human purified enzyme (Prolastin®). *Br J Dermatol*. 2002;147:1258-1261.
12. Ortiz P, Skov B, Benfeldt E. Alpha-antitrypsin deficiency-associated panniculitis: case report and review of treatment options. *J Eur Acad Dermatol Venereol*. 2005;19(4):487-490.
13. Geraminejad P, DeBloom JR, Walling HW, et al. Alpha-1-antitrypsin associated panniculitis: the MS variant. *J Am Acad Dermatol*. 2004;51(4):645-655.
14. Kjus T, Lutzow-Holm C, Christensen OB. Treatment of panniculitis associated with alpha-1-antitrypsin deficiency with alpha-1-protease inhibitor. *Acta Derm Venereol*. 2003;83(6):462-463.
15. Valverde R, Rosales B, Ortiz-de Frutos FJ, et al. Alpha-1-antitrypsin deficiency panniculitis. *Dermatol Clin*. 2008;26:447-451.
16. Lyon MJ. Metabolic panniculitis: alpha-1 antitrypsin deficiency panniculitis and pancreatic panniculitis. *Dermatol Ther*. 2010;23:368-374.
17. Olson JM, Moore EC, Valasek MA, et al. Panniculitis in alpha-1 antitrypsin deficiency treated with enzyme replacement. *J Am Acad Dermatol*. 2012;66:e139-e141.
18. Elsensohn AN, Curtis JA, Secrest AM, et al. Alpha-1-antitrypsin deficiency panniculitis presenting with severe anasarca, pulmonary embolus and hypogammaglobulinaemia. *Br J Dermatol*. 2015;173:288-314.
19. Elsensohn AN, Liaqat M, Powell G, et al. Alpha-1-antitrypsin associated panniculitis and corneal ulcer with a rare allelic variant (PiFZ): a case report. *Int J Dermatol*. 2015, October 16 [Epub ahead of Print].
20. Sabbagh DK, Barmayehvar B, Nguyen T, Edgar RG, Turner AM. Managing panniculitis in alpha-1 antitrypsin deficiency: systematic review of evidence behind treatment. *World J Dermatol*. 2018;7(1):1-8.
21. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2019. Available at: <https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf>. Accessed on September 12, 2019.
22. Griesse M, Latzin P, Kappler M, et al. Alpha₁-antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients. *Eur Respir J*. 2007;29(2):240-250.
23. Martin SL, Downey D, Bilton D, et al, on behalf of the Recombinant AAT CF Study Team. Safety and efficacy of recombinant alpha₁-antitrypsin therapy in cystic fibrosis. *Pediatr Pulmonol*. 2006;41:177-183.